Table 1 Clinical and laboratory assessment in 30 JIA patients with 40 symptomatic ankles*

Sex

   Male

9 (30%)

   Female

21 (70%)

Subgroups

   RF-negative polyarthritis

11 (37%)

   Oligoarthritis extended

6 (20%)

   Oligoarthritis persistent

13 (43%)

   Other subgroups

0

Age at injection, years

6.5

1-16

Disease duration, years

2.0

0.5-13.9

Number of joints (n = 40) with

   Swelling

38 (95%)

   Pain

35 (88%)

   Tenderness at palpation

39 (98%)

   Limited range of motion

34 (85%)

   Active arthritis

40 (100%)

VAS ankle pain patient/parent, cm

3.5

0.2-10.0

VAS global assessment patient/parent, cm

0.6

0-9.7

VAS global assessment physician, cm

2.8

1-6.8

CRP level, mg/l

2

0-22

ESR, mm/hour

14

8-69

HLA B27 positive, number of patients

5 (17%)

ANA positive, number of patients

14 (47%)

Second-line drug therapy

   Methotrexate

15 (50%)

Biologic therapies

   Etanercept

3 (10%)

   Adalimumab

2 (7%)

   Abatacept

1 (3%)

Systemic corticosteroid therapy

5 (17%)